Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial

Valneva today announced that it has completed recruitment for the pivotal Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.

The Company also initiated an antibody persistence trial to follow the immunogenicity of a subset of participants for a period of five years.

Read more